Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy

Nutrition Journal

Table 2 Linear models for 25(OH)D levels (ng/mL) at baseline and at week 24 for responders (n = 52)

Part A.
	Baseline (n = 97)
	Unadjusted model	Adjusted model
	Beta (95 % CI)	Beta (95 % CI)
Female sex	−1.08 (−7.27, 5.12)	−5.57 (−11.40, 0.26)
Age (years)	−0.16 (−0.44, 0.11)	−0.20 (−0.46, 0.05)
Non-white race/ethnicity	2.48 (−3.29, 8.25)	2.64 (−2.78, 8.06)
Nadir CD4+ T lymphocyte (per 100 cells/mm³)	0.57 (−2.04, 3.18)	1.17 (−1.42, 3.75)
Current use of TDF	5.84 (−0.43, 12.12)
Current use of AZT	−5.27 (−11.44, 0.89)
Current use of EFV	−1.65 (−7.96, 4.66)
Current use of PI	−2.85 (−3.55, 9.30)	6.93 (0.96, 12.90)
Part B.
	Week 24^a (n = 52)
	Unadjusted model	Adjusted model
	Beta (95 % CI)	Beta (95 % CI)
Female sex	−4.08 (−16.61, 8.46)	−0.96 (−14.20, 12.27)
Age (years)	−0.22 (−0.78, 0.33)	0.21 (−0.38, 0.79)
Non-white race/ethnicity	−5.02 (−16.95, 6.91)	−5.53 (−17.82, 6.77)
Nadir CD4+ T lymphocyte (per 100 cells/mm³)	1.94 (−3.44, 7.31)	3.29 (−1.96, 8.54)
Baseline 25(OH)D	1.17 (0.25, 2.09)	1.27 (0.24, 2.30)
Current use of TDF	−10.24 (−22.50, 2.02)
Current use of AZT	7.44 (−4.70, 19.57)
Current use of EFV	17.88 (4.08, 31.68)	21.09 (6.41, 35.78)
Current use of PI	−16.15 (−31.10, −2.13)

25(OH)D 25-hydroxyvitamin D, TDF tenofovir, AZT zidovudine, EFV efavirenz, PI protease inhibitor
^aFor those who underwent vitamin D supplementation and achieved 25(OH)D levels > 30 ng/mL at week 24
Bold font implies statistically significant results assuming a 5% significance threshold

ISSN: 1475-2891